Literature DB >> 22290218

HCC: current surgical treatment concepts.

F Cauchy1, D Fuks, J Belghiti.   

Abstract

PURPOSE: The purpose of this study is to review indications and results of surgical treatments of hepatocellular carcinoma (HCC). This tumor, which represents one of the most common malignancies worldwide, is characterized by its prominent development in patients with chronic liver disease (CLD). Liver transplantation (LT) is considered as the ideal treatment of limited HCC removing both tumor(s) and the pre-neoplasic underlying diseased liver. However, this treatment, which is not available in many countries, is restricted to patients with minimum risk of tumor recurrence under immunosuppression. The risk of recurrence is minimized in patients fulfilling the Milan criteria with a tendency to accept slight expansion of size in patients with favourable natural history and low AFP level. Increasing duration in the waiting list before LT leads several teams to use neoadjuvant therapies such as percutaneous ablation, TACE and liver resection. Liver resection in cirrhotic patients with good liver function remains the most available efficient treatment of patients with HCC. Better liver function assessment, understanding of the segmental liver anatomy with more accurate imaging studies and surgical technique refinements are the most important factors that have contributed to reduce mortality with an expecting 5 years survival of 70%. There is considerable interest in combined treatment associating resection and LT. Transplantable patients with good liver function should be considered for liver resection as primary therapy and for LT in case of tumor recurrence. This salvage strategy is refined using pathological analysis of the resected specimen which identifies histological pejorative factors allowing selecting patients who should transplanted before recurrence.
CONCLUSIONS: The improvement of survival in HCC patients after surgical treatment results from refinements in surgical technique and better identification of adverse prognostic factors.

Entities:  

Mesh:

Year:  2012        PMID: 22290218     DOI: 10.1007/s00423-012-0911-2

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  150 in total

1.  Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma.

Authors:  Yun-Quan Luo; Yi Wang; Han Chen; Meng-Chao Wu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2002-11

2.  A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Authors:  Wei-Ping Zhou; Eric C H Lai; Ai-Jun Li; Si-Yuan Fu; Jian-Ping Zhou; Ze-Ya Pan; Wan Yee Lau; Meng-Chao Wu
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

3.  Preoperative estimation of remnant hepatic function using fusion images obtained by (99m)Tc-labelled galactosyl-human serum albumin liver scintigraphy and computed tomography.

Authors:  Y Yumoto; T Yagi; S Sato; K Nouso; Y Kobayashi; M Ohmoto; E Yumoto; I Nagaya; H Nakatsukasa
Journal:  Br J Surg       Date:  2010-06       Impact factor: 6.939

Review 4.  Hepatocellular nodules in liver cirrhosis: contrast-enhanced ultrasound.

Authors:  Tae Kyoung Kim; Kyoung Ho Lee; Korosh Khalili; Hyun-Jung Jang
Journal:  Abdom Imaging       Date:  2011-06

5.  Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Authors:  Jessica Y Leung; Andrew X Zhu; Fredric D Gordon; Daniel S Pratt; Abigail Mithoefer; Kathryn Garrigan; Adam Terella; Martin Hertl; A Benedict Cosimi; Raymond T Chung
Journal:  Liver Transpl       Date:  2004-11       Impact factor: 5.799

6.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

Review 7.  The surgical approach to HCC: our progress and results in Japan.

Authors:  Masatoshi Makuuchi; Keiji Sano
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

8.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

9.  Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis.

Authors:  S T Fan; E C Lai; C M Lo; I O Ng; J Wong
Journal:  Arch Surg       Date:  1995-02

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  26 in total

1.  Outcomes of central bisectionectomy for hepatocellular carcinoma.

Authors:  Thomas K Gallagher; Albert C Y Chan; Ronnie T P Poon; Tan To Cheung; Kenneth S H Chok; See Ching Chan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-11-21       Impact factor: 3.647

2.  CCAT1 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Huaqiang Zhu; Xu Zhou; Hong Chang; Hongguang Li; Fangfeng Liu; Chaoqun Ma; Jun Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Impact of Glissonean pedicle approach for centrally located hepatocellular carcinoma in mongolia.

Authors:  Jigjidsuren Chinburen; Michele Gillet; Masakazu Yamamoto; Tsiiregzen Enkh-Amgalan; Erdenebileg Taivanbaatar; Chinbold Enkhbold; Puntsagdulam Natsagnyam
Journal:  Int Surg       Date:  2015-02

4.  Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.

Authors:  Jian-Yong Lei; Lu-Nan Yan; Wen-Tao Wang
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

5.  Laparoscopic liver resection for hepatocellular carcinoma in cirrhotic patients: 10-year single-center experience.

Authors:  Ahmed Shehta; Ho-Seong Han; Yoo-Seok Yoon; Jai Young Cho; YoungRok Choi
Journal:  Surg Endosc       Date:  2015-06-20       Impact factor: 4.584

Review 6.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

Review 7.  Impact of aging on morbidity and mortality after liver resection: a systematic review and meta-analysis.

Authors:  Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Kenji Okita; Shigenori Ota; Masayuki Ishii; Tomomi Ueki; Toshihiko Nishidate; Yasutoshi Kimura; Tomohisa Furuhata; Koichi Hirata
Journal:  Surg Today       Date:  2014-02-14       Impact factor: 2.549

8.  GAB2 promotes cell proliferation by activating the ERK signaling pathway in hepatocellular carcinoma.

Authors:  Yuyan Chen; Qingqing Liu; Miaomiao Wu; Manhua Li; Haifang Ding; Xiaohang Shan; Jinxia Liu; Tao Tao; Runzhou Ni; Xudong Chen
Journal:  Tumour Biol       Date:  2016-03-30

9.  Risk factors of hospital mortality after re-laparotomy for post-hepatectomy hemorrhage.

Authors:  Tian Yang; Li Li; Qian Zhong; Wan Yee Lau; Han Zhang; Xing Huang; Wei-Feng Yu; Feng Shen; Jie-Wei Li; Meng-Chao Wu
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

10.  Inferior right hepatic vein-preserving major right hepatectomy for hepatocellular carcinoma in patients with significant fibrosis or cirrhosis.

Authors:  Chunping Jiang; Zhongxia Wang; Qingxiang Xu; Xingyu Wu; Yitao Ding
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.